
Past Psychiatric Conditions as Risk Factors for Postpartum Depression: A Nationwide Cohort Study
Instructions
Click the red REGISTER button to pay the $10 fee and take the posttest.
Click here to return to the JCP CME article.
Overview
What characteristics affect patients’ risk for postpartum depression? In what time frame is the risk greatest? Dr Johansen and colleagues analyzed a large US cohort to answer these questions. Find their results in this CME journal article.
To cite: Johansen SL, Stenhaug BA, Robakis TK, et al. Past psychiatric conditions as risk factors for postpartum depression: a nationwide cohort study. J Clin Psychiatry. 2020;81(1):19m12929.
To share: https://doi.org/10.4088/JCP.19m12929
Read the whole article at psychiatrist.com here:
Past Psychiatric Conditions as Risk Factors for Postpartum Depression: A Nationwide Cohort Study
© Copyright 2020 Physicians Postgraduate Press, Inc.
Target Audience
Psychiatrists
Learning Objectives
Evaluate patients’ psychiatric history to identify women at increased risk for postpartum depression
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Evaluate patients’ psychiatric history to identify women at increased risk for postpartum depression
Release, Expiration, and Review Dates
This educational activity was published in January 2020 and is eligible for AMA PRA Category 1 Credit™ through February 28, 2022. The latest review of this material was December 2019.
Statement of Need and Purpose
Although screening new mothers for postpartum depression (PPD) is recommended by guidelines, many clinicians do not do so regularly. Education about risk factors for PPD would be beneficial to clinicians to improve their awareness of the condition and which patients are especially susceptible to it. This would encourage them to spur discussion of PPD with patients and conduct continued screening in high-risk patients.
Disclosure of off-label usage
The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.
Funding/support
This research was supported by the Stanford University School of Medicine Medical Scholars Fellowship in Stanford, California. This fellowship provided tuition and stipend to support the first author in full-time research.
Role of the Sponsor
The funding was not used for the conduct or publication of this study.
Previous Presentation
Poster presentation at the Annual Meeting of the American Psychiatric Association; May 5–9, 2018; New York, New York.
Additional Information
Authors obtained full access to Optum© Clinformatics Data Mart through the Stanford University Center for Population Health Sciences. Access to this data set is ongoing.
Faculty Affiliation
Sara L. Johansen, MD*
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California
Ben A. Stenhaug, BS
Stanford University Graduate School of Education, Stanford, California
Thalia K. Robakis, MD, PhD
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California
Katherine E. Williams, MD
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California
Mark R. Cullen, MD
Center for Population Health Sciences, Stanford University, Palo Alto, California
*Corresponding author: Sara L. Johansen, MD, Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Rd, Stanford, CA 94305 (sara.johansen@stanford.edu).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.
Drs Johansen, Robakis, Williams, and Cullen and Mr Stenhaug have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation